Skip to content

Omeros OMER Net Change in Cash

Net Change in Cash at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$13.25M-109%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$134.46M+2,610%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Vor Biopharma logo
Vor BiopharmaVOR
-$226.61M-610%
Annexon logo
AnnexonANNX
$13.16M-72.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$21M-150%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's net change in cash?
Omeros (OMER) reported net change in cash of -$7.75M in Q1 2026.
How has Omeros's net change in cash changed year-over-year?
Omeros's net change in cash decreased by 1000.6% year-over-year, from $861K to -$7.75M.
What is the long-term trend for Omeros's net change in cash?
Over 2 years (2021 to 2025), Omeros's net change in cash has grown at a -73.7% compound annual growth rate (CAGR), from $90.31M to $6.26M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.